Switch theme
Sign up to access all valuation multiples
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
2009
184
LTM Revenue $8.7M
LTM EBITDA -$69.5M
$245M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nyxoah has a last 12-month revenue (LTM) of $8.7M and a last 12-month EBITDA of -$69.5M.
In the most recent fiscal year, Nyxoah achieved revenue of $5.1M and an EBITDA of -$59.3M.
Nyxoah expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nyxoah valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.7M | XXX | $5.1M | XXX | XXX | XXX |
| Gross Profit | $6.3M | XXX | $3.3M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | -$69.5M | XXX | -$59.3M | XXX | XXX | XXX |
| EBITDA Margin | -797% | XXX | -1169% | XXX | XXX | XXX |
| EBIT | -$78.0M | XXX | -$66.1M | XXX | XXX | XXX |
| EBIT Margin | -894% | XXX | -1301% | XXX | XXX | XXX |
| Net Profit | -$78.7M | XXX | -$66.5M | XXX | XXX | XXX |
| Net Margin | -902% | XXX | -1310% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nyxoah's stock price is EUR 7 (or $8).
Nyxoah has current market cap of EUR 259M (or $291M), and EV of EUR 218M (or $245M).
See Nyxoah trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $245M | $291M | XXX | XXX | XXX | XXX | $-2.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nyxoah has market cap of $291M and EV of $245M.
Nyxoah's trades at 48.3x EV/Revenue multiple, and -4.1x EV/EBITDA.
Equity research analysts estimate Nyxoah's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nyxoah has a P/E ratio of -3.7x.
See valuation multiples for Nyxoah and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $291M | XXX | $291M | XXX | XXX | XXX |
| EV (current) | $245M | XXX | $245M | XXX | XXX | XXX |
| EV/Revenue | 28.1x | XXX | 48.3x | XXX | XXX | XXX |
| EV/EBITDA | -3.5x | XXX | -4.1x | XXX | XXX | XXX |
| EV/EBIT | -3.1x | XXX | -3.7x | XXX | XXX | XXX |
| EV/Gross Profit | 39.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.7x | XXX | -4.4x | XXX | XXX | XXX |
| EV/FCF | -3.3x | XXX | -3.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNyxoah's last 12 month revenue growth is 221%
Nyxoah's revenue per employee in the last FY averaged $28K, while opex per employee averaged $0.4M for the same period.
Nyxoah's rule of 40 is -746% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nyxoah's rule of X is -244% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nyxoah and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 221% | XXX | 208% | XXX | XXX | XXX |
| EBITDA Margin | -797% | XXX | -1169% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -746% | XXX | -947% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -244% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $28K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 761% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1366% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nyxoah acquired XXX companies to date.
Last acquisition by Nyxoah was XXXXXXXX, XXXXX XXXXX XXXXXX . Nyxoah acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nyxoah founded? | Nyxoah was founded in 2009. |
| Where is Nyxoah headquartered? | Nyxoah is headquartered in Belgium. |
| How many employees does Nyxoah have? | As of today, Nyxoah has 184 employees. |
| Who is the CEO of Nyxoah? | Nyxoah's CEO is Mr. Olivier Taelman. |
| Is Nyxoah publicy listed? | Yes, Nyxoah is a public company listed on BRU. |
| What is the stock symbol of Nyxoah? | Nyxoah trades under NYXH ticker. |
| When did Nyxoah go public? | Nyxoah went public in 2020. |
| Who are competitors of Nyxoah? | Similar companies to Nyxoah include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Nyxoah? | Nyxoah's current market cap is $291M |
| What is the current revenue of Nyxoah? | Nyxoah's last 12 months revenue is $8.7M. |
| What is the current revenue growth of Nyxoah? | Nyxoah revenue growth (NTM/LTM) is 221%. |
| What is the current EV/Revenue multiple of Nyxoah? | Current revenue multiple of Nyxoah is 28.1x. |
| Is Nyxoah profitable? | Yes, Nyxoah is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nyxoah? | Nyxoah's last 12 months EBITDA is -$69.5M. |
| What is Nyxoah's EBITDA margin? | Nyxoah's last 12 months EBITDA margin is -797%. |
| What is the current EV/EBITDA multiple of Nyxoah? | Current EBITDA multiple of Nyxoah is -3.5x. |
| What is the current FCF of Nyxoah? | Nyxoah's last 12 months FCF is -$73.5M. |
| What is Nyxoah's FCF margin? | Nyxoah's last 12 months FCF margin is -843%. |
| What is the current EV/FCF multiple of Nyxoah? | Current FCF multiple of Nyxoah is -3.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
